Prurigo Nodularis

Below is a list of our prurigo nodularis studies that are currently enrolling.

Topical Ruxolitinib Evaluation in Prurigo Nodularis

Population: Patients aged eighteen years and older
Study Condition: Prurigo Nodularis
Study Design: The purpose of this research study is to determine if an investigational cream, ruxolitinib 1.5% cream, is safe and effective to treat adults with prurigo nodularis. In this study, ruxolitinib cream will be compared to a “vehicle cream.” The vehicle cream looks like the ruxolitinib cream but contains no ruxolitinib. This study can last up to 60 weeks, including up to 4 weeks for screening, up to 52 weeks for treatment, and 30 days for safety follow-up. Eligible participants will be randomized 1:1 to receive ruxolitinib 1.5% cream or vehicle cream for the first 12 weeks. For the following 40 weeks all participants will receive the ruxolitinib cream.
Compensation will be provided

Please contact Dr. Veronica Emmerich for more information regarding ongoing prurigo nodularis studies.